[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Marker Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":101},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100558333","phase-1-mt-601-administered-to-patients-with-locally-advanced-unresectable-or-metastatic-pancreatic-cancer-100558333",false,"NCT06549751","MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer","A Phase 1 Study With Expansion of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer (PANACEA)","PANACEA","Inclusion Criteria:\n\n1. Informed Consent\n2. Age ≥ 18 years\n3. ECOG performance status of 0 to 1\n4. Cytologically or histologically confirmed, locally advanced, unresectable or metastatic pancreatic adenocarcinoma (pancreatic carcinomas with at least some component of adenocarcinoma included).\n5. Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n6. Prior receipt of at least 4 doses (\\~2 months) of FFX or NLX with plans for completion of 12 doses (\\~6 months)\n7. Absence of progression during treatment with FFX or NLX (eg. CR, PR, or SD at study entry)\n8. Adequate pulmonary function with partial pressure of oxygen (pO2) on room air of at least 90%\n9. Adequate cardiac function with an ejection fraction ≥ 45%\n10. Adequate organ function, as defined below:\n\n    * Absolute neutrophil count (ANC) ≥1.0 × 109\u002FL (growth factor support allowed)\n    * Platelets ≥75,000\u002Fmm3 (supportive medications allowed)\n    * Hemoglobin ≥9 gm\u002FdL (transfusion allowed)\n    * Total bilirubin ≤2.0 × ULN unless considered due to Gilbert's syndrome in which case, ≤ 3.0 x ULN\n    * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN OR ≤5 × ULN if known tumor involvement of liver\n    * Serum creatinine ≤2 × ULN OR estimated glomerular filtration rate (using institutional standard) ≥50 mL\u002Fmin\n11. Willingness to use adequate contraception throughout study and for a period of 3 months after last dose of any study drugs\n\nExclusion Criteria:\n\n1. Known CNS metastases or meningeal carcinomatosis unless treated and controlled for ≥ 3 months prior to the first administration of MT-601 without the need for increasing doses of steroids\n2. Other known active cancer likely to require additional treatment in the next 2 years unless approved by Medical Monitor\n3. Active bacterial, viral, or fungal infection requiring systemic therapy. Patients may be re-evaluated for eligibility upon completion of infection treatment.\n4. Significant cardiovascular risk (eg, coronary stenting within 4 weeks, myocardial infarction within 6 months)\n5. Diagnosis of significant immunodeficiency that in the Investigator or Medical Monitor's judgment would preclude participation in the study.\n6. Administration of systemic steroid therapy (\\> 10 mg\u002Fday of prednisone equivalent) ≤ 7 days prior to the first administration of MT-601\n7. Active autoimmune disease that required systemic treatment in the past 2 years (replacement therapies excluded \\[eg, thyroxine, insulin, physiologic corticosteroids\\])\n8. History of solid organ or hematologic transplant\n9. Known HIV\n10. Evidence of active hepatitis B as defined by:\n\n    1. Positive hepatitis B surface antigen (HBsAg), or\n    2. Negative HBsAg but a positive hepatitis B surface antibody (HBsAb) or positive hepatitis B core antibody (HBcAb) with a positive hepatitis B virus (HBV) DNA\n11. Evidence of active hepatitis C as defined by:\n\n    a. Positive anti-hepatitis C virus antibody (HCVAb) with a positive hepatitis C virus (HCV) RNA by PCR\n12. Pregnant or currently breast-feeding\n13. Psychiatric illness\u002Fsocial situations that would interfere with compliance with study requirements","ALL","18 Years",{"count":20,"type":21},38,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to assess safety and tolerability of escalating doses of MT-601 administered during the off week of chemotherapy regimen for patients with pancreatic cancer. The main question\\[s\\] it aims to answer are: safety and efficacy • overall response rate and duration of response. Participants will meet all applicable inclusion criteria prior to chemotherapy and must agree to provide apheresis material.",[27,28,29],"Pancreas Cancer","Pancreatic Cancer Metastatic","Pancreatic Cancer (Unresectable)","NOT_YET_RECRUITING","2026-05-10",{"date":33,"type":34},"2026-05-13","ACTUAL",{"date":36,"type":21},"2026-07-16",{"date":38,"type":21},"2028-09-16",{"name":40,"class":41},"Marker Therapeutics, Inc.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":5},"100558538","phase-1-safety-of-mt-401-ots-in-patients-with-relapsed-aml-or-mds-100558538","NCT06552416","Safety of MT-401-OTS in Patients With Relapsed AML or MDS","A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)","RAPID","Inclusion Criteria:\n\n* General\n\n  1. Must be ≥ 65 years of age and capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol, at the time of signing the ICF\n  2. Must have a life expectancy ≥ 12 weeks\n  3. Must have an ECOG performance status of 0-2\n  4. Must have available MT-401-OTS product with a ≥ 2\u002F8 HLA match Disease Characteristics\n  5. For participants with AML:\n\n     1. Must have a confirmed diagnosis of AML or MDS\u002FAML per 2022 WHO Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\u002FDendritic Neoplasms or 2022 International Consensus Criteria\n     2. Must have intermediate or high-risk disease based on ELN 2022 criteria.\n     3. If no targetable mutation is present, must have received 1 prior standard regimen with at least 4 cycles of standard therapy containing an HMA or a standard cytarabine-containing induction therapy\n     4. If targetable mutation is present, must have received a regimen that includes commercially available targeted therapy unless unable to tolerate or the participant declines (must be documented in the informed consent). If targeted therapy was not administered as part of first-line of therapy, a second regimen is allowed.\n     5. Must have either: ≤ 10% bone marrow blasts and ≤ 5% peripheral blasts during screening and not be considered to have hyperproliferating disease at diagnosis or after treatment OR Evidence of MRD based on evaluation at a local laboratory\n  6. For participants with MDS:\n\n     1. Must have confirmed diagnosis of MDS based on 2022 WHO Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\u002FDendritic Neoplasms or 2022 ICC criteria\n     2. Must have high-risk or very-high-risk disease based on IPSS-M (ie, not evolved to AML)\n     3. Must have received standard treatment with at least 4 cycles of an HMA and have evidence of continued disease, including morphologic disease or MRD-positive\n     4. Must have bone marrow blasts ≤ 10% at screening Health Status\n  7. Must have adequate coagulation, hepatic, renal, and cardiac function:\n\n     1. PT\u002FINR and PTT\u002FaPTT \\\u003C 1.3 × ULN\n     2. AST and ALT \\\u003C 3 × ULN; for participants with leukemic infiltration of the liver (documented by biopsy or imaging), AST and ALT \\\u003C 5 × ULN is permitted.\n     3. Total bilirubin ≤ 1.5 × ULN unless bilirubin rise is due to Gilbert's syndrome or of nonhepatic origin (2 × ULN is permitted)\n     4. eGFR ≥ 40 mL\u002Fmin by the MDRD formula\n     5. LVEF ≥ 45% (prior to apheresis and lymphodepletion) Sex\n  8. Women of childbearing potential are eligible to participate if they agree to the following during the intervention period and for at least 1 year after the last infusion of MT-401-OTS:\n\n     1. Must use a contraceptive method that is highly effective (ie, with a failure rate of \\\u003C 1% per year; see Section 10.3), preferably with low user dependency PLUS\n     2. Must agree not to donate eggs (ie, ova and oocytes) for the purpose of reproduction\n  9. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 6 months after the last infusion of MT-401-OTS:\n\n     1. Must refrain from donating sperm\n\n        PLUS either:\n     2. Must be abstinent from intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR\n     3. Must agree to use a male condom AND should also be advised of the benefit for a nonpregnant female partner to use a highly effective method of contraception (see Section 10.3) as a condom may break or leak\n\nExclusion Criteria:\n\n* Disease-Related\n\n  1. Have leukemic involvement in the CNS\n  2. Have other extramedullary disease involvement (except hepatosplenic involvement)\n  3. Have APL Medical Conditions\n  4. Have primary immunodeficiency\n  5. Have severe or uncontrolled autoimmune disorder\n  6. Have a history or presence of clinically relevant CNS pathology, such as epilepsy, seizure, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome or psychosis\n  7. Have active malignancies (ie, those that are progressing or have required treatment change in the last 24 months) other than the disease being treated under study. Exceptions to this inclusion include the following:\n\n     1. Nonmelanoma skin cancer treated within the last 24 months that is considered completely cured\n     2. Adequately treated breast lobular carcinoma in situ and breast ductal carcinoma in situ\n     3. Adequately treated cervical carcinoma in situ without evidence of disease\n     4. History of localized breast cancer and receiving antihormonal agents, or history of localized prostate cancer (N0M0) and receiving androgen-deprivation therapy\n     5. A malignancy that is considered cured with minimal risk of recurrence\n  8. Have any active systemic infection requiring therapy (viral, bacterial, or fungal), including HIV\n  9. Have active hepatitis B or C infection or other clinically active liver diseases, as defined below:\n\n     1. Seropositivity for hepatitis B as defined by a positive test for HbsAg Participants with resolved infection (ie, participants who are HbsAg-negative with antibodies to total anti-HBc with or without the presence of anti-HBs) must be screened using RT-PCR measurement of HBV DNA levels. Those who are RT PCR-positive will be excluded.\n\n        Participants with serologic findings suggestive of HBV vaccination (anti HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by RT PCR.\n     2. Active hepatitis C infection as defined by being positive for a nucleic acid test for HCV RNA\n  10. Have Class III or IV congestive heart failure per New York Association\n  11. Have unstable angina\n  12. Have a history or evidence of current, uncontrolled, clinically significant, unstable arrhythmias\n  13. Have an oxygen saturation on room air of ≤ 92%\n  14. Have clinically significant reversible nonhematologic toxicities from prior cancer therapy that have not recovered to Grade 1 or baseline Note: Participants with clinically nonsignificant toxicities, such as asymptomatic laboratory values, will be allowed on study.\n\n      Prior\u002FConcomitant Therapies\n  15. Received prior treatments for underlying malignancy, except as specified in the Inclusion Criteria. Participants with AML secondary to MDS may have received prior treatment for MDS.\n  16. Have had prior HSCT\n  17. Are receiving concurrent therapies other than HMA, as delineated in the study design\n  18. Have received hematopoietic growth factors within 2 days of lymphodepleting conditioning regimen\n  19. Have a history of severe allergic reactions\u002Fintolerance to any of the study intervention components, including the conditioning regimen, HMA, or DSMO, or to tocilizumab\n  20. Have had major surgery within 14 days (central line placement allowed)\n  21. Have received systemic steroids (exception: physiological doses of steroids allowed) or other immunosuppressive therapies within 14 days prior to lymphodepleting conditioning regimen Other\n  22. Are unable to be matched with MT-401-OTS product inventory\n  23. Are pregnant or breastfeeding\n  24. Have any other issue that, in the opinion of the treating physician, would make the participant ineligible for the study or unable to comply with its requirements","65 Years",{"count":53,"type":21},40,[24],"This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and\u002For \\\u003C\u002F= 10% blast following prior induction therapy or at least 4 cycles of nonintensive therapy and 2) those with high- or very-high-risk MDS per 2023 IWG criteria and who have residual disease with \\\u003C\u002F= 10% blasts following treatment with an HMA-based therapy.",[57,58],"Acute Myeloid Leukemia, in Relapse","MDS","RECRUITING","2025-12-08",{"date":62,"type":34},"2025-12-16",{"date":64,"type":34},"2025-06-16",{"date":66,"type":21},"2029-09",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":89,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100500641","phase-1-safety-and-preliminary-efficacy-of-mt-601-in-patients-with-relapsedrefractory-lymphoma-100500641","NCT05798897","Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed\u002FRefractory Lymphoma","A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)","APOLLO","Inclusion Criteria:\n\n* All applicable inclusion and exclusion criteria must be met at Screening and at Baseline (re-assessment of eligibility within 14 days prior to group assignment).\n\nParticipants are eligible to be included in the study only if all of the following criteria apply and the participant, in the judgement of the Investigator, is an appropriate candidate for experimental therapy:\n\nGeneral:\n\n1. Participant must be ≥ 18 years of age and capable of giving signed informed consent (ICF), which includes compliance with the requirements and restrictions listed in the ICF and in the protocol, at the time of signing the ICF.\n\n   Disease Specific:\n2. Cytologically or histologically confirmed diagnosis of NHL, HL or CLL based on the 2022 World Health Organization (WHO) criteria for hematolymphoid neoplasms\n3. Enrollment of the following subtypes will be eligible:\n\n   1. LBCL including diffuse large B cell lymphoma, primary mediastinal B cell lymphoma (PMBCL), high grade B cell lymphoma (HGBL), T cell rich B cell lymphoma and transformed indolent lymphoma (transformed iNHL)\n   2. FL\n   3. MCL\n   4. MZL\n   5. HL\n\n      The following additional subtypes may be enrolled in disease specific cohorts during Dose Expansion (upon approval by Sponsor)\n   6. CLL\u002FSLL\n   7. CNS lymphoma\n   8. CAR T cell refractory\n4. Must have measurable disease as per 2014 Lugano criteria or 2018 iwCLL criteria. Participants with splenic MZL must have measurable splenomegaly on imaging or evidence of bone marrow involvement.\n\n   Prior Treatments\n5. Participants who are R\u002FR, are intolerant to, or are considered ineligible for systemic standard of care anticancer treatments, including at least 2 prior therapies. Participants who refuse standard of care treatments may also be considered if documentation is provided that he\u002Fshe has been made aware of all therapeutic options.\n6. For participants with LBCL, FL, and MCL: Have received CD19-directed CAR T cell therapy and relapsed ≥ 30 days or attained an incomplete response as the best response within 1 year after CAR T cell administration. Participants who refuse or are ineligible for CAR T cell therapy are eligible for this study. Note: during Dose Expansion, a specific cohort may be enrolled to evaluate participants who were refractory to CD19-directed CAR T cell therapy.\n\n   Health Status\n7. Karnofsky score of ≥70 or performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale\n8. Life expectancy ≥12 weeks\n9. Adequate blood, liver, renal and cardiac function:\n\n   1. Hematology: Hemoglobin ≥ 7.0 g\u002FdL (can be transfused), absolute lymphocyte count (ALC) ≥ 300\u002FμL, (prior to apheresis only), absolute neutrophil count (ANC) ≥ 750\u002FμL and platelet count ≥ 50,000\u002FμL (prior to the conditioning regimen only)\n   2. Liver: Bilirubin ≤ 1.5X upper limit of normal (ULN) (exception of bilirubin elevation due to Gilbert's syndrome 3X); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3X ULN\n   3. Renal: Serum creatinine ≤ 1.5X ULN or measured or calculated creatinine clearance ≥ 50 mL\u002Fmin (prior to the conditioning regimen)\n   4. Cardiac: left ventricular ejection fraction ≥ 45% (prior to the leukapheresis) Sex\n10. Female: Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective (i.e., with a failure rate of \\\u003C 1% per year), preferably with low user dependency during the intervention period and for at least 6 months after the last infusion of MT-601 and agrees not to donate eggs (i.e., ova and oocytes) for the purpose of reproduction during this period\n11. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 6 months after the last infusion of MT-601:\n\nRefrain from donating sperm\n\nPLUS either:\n\nBe abstinent from intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR Must agree to use a male condom AND should also be advised of the benefit for a nonpregnant female partner to use a highly effective method of contraception as a condom may break or leak\n\nExclusion Criteria:\n\n* Patients are excluded from the study if any of the following criteria apply:\n\nDisease-related\n\n1. Evidence of bulky disease at the time of the conditioning regimen (≥ 10 cm in diameter for LBCL or HL and \\> 6 cm for other subtypes)\n2. Untreated or ongoing treatment for CNS lymphoma or completed treatment within 2 weeks of apheresis (Note: May be allowed in Dose Expansion if disease specific cohort for CNS lymphoma is opened)\n3. Refractory to CAR T therapy defined as a best response of stable disease or disease progression (Note: May be allowed in Dose Expansion if disease specific cohort for CAR T cell therapy refractory is opened)\n4. Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression Medical Conditions\n5. Primary immunodeficiency\n6. Severe or uncontrolled autoimmune disorder\n7. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis\n8. Unresolved immune effector cell-associated neurotoxicity syndrome (ICANS) from prior CAR T cell administration. Consideration for Grade 1 may be made after discussion with the Medical Monitor\n9. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast, and\u002For prostate) unless disease free for at least 3 years\n10. Cardiac conditions:\n\n    1. Medically uncontrolled hypertension (≥ 160 mmHg systolic blood pressure or ≥ 100 mmHg diastolic blood pressure)\n    2. Congestive heart failure Class ≥ II as defined by the New York Heart Association\n    3. Acute coronary syndrome (including unstable angina, coronary artery stenting, or angioplasty, bypass grafting within prior 6 months)\n    4. History or evidence of current, uncontrolled, clinically significant, unstable arrhythmias\n11. Oxygen saturation at room air \\\u003C 92%\n12. Participant has known human immunodeficiency virus (HIV) infection, or active hepatitis B virus (HBV)\u002Fhepatitis C virus (HCV) infection\n13. Acute bacterial, viral, fungal infection requiring systemic therapy (uncomplicated urinary tract infection and bacterial pharyngitis are permitted if responding to therapy)\n14. History of severe allergic reactions to any of the study intervention components including conditioning regimen, dimethyl sulfoxide (DMSO) or to tocilizumab\n15. Clinically significant reversible toxicities from prior cancer therapy that have not recovered to Grade 1 or baseline\n\n    * Participants with Grade 2 neuropathies due to prior treatment will be allowed on study.\n    * Participants with clinical nonsignificant toxicities, such as alopecia, will be allowed on study.\n\n    Prior\u002FConcomitant Therapy\n\n    Prior to Apheresis:\n16. Receipt of allogeneic hematopoietic cell transplant (HCT) within 12 months; on immunosuppression or with evidence of donor\u002Fmixed chimera\n17. Receipt of autologous HCT within 3 months\n18. Treatment with CD19-directed CAR T cell therapy within 3 months\n19. Treatment with bispecific antibody within 1 month\n20. Treatment with antibody drug conjugates (ADC's) or PD-1\u002FPD-L1 within 21 days\n21. Treatment with monoclonal antibodies impacting T cell function within 14 days\n22. Treatment with systemic immunosuppression including systemic corticosteroids (unless ≤5 mg\u002Fday oral prednisone or steroid equivalent) within 14 days\n23. Treatment with chemotherapy within 7 days\n\n    Prior to the conditioning regimen:\n24. Treatment with a live, attenuated vaccine within 4 weeks\n25. Treatment with antibody drug conjugates (ADC's) or PD-1\u002FPD-L1 within 21 days\n26. Treatment with chemotherapy or biologics\u002Fmonoclonal antibodies within 14 days\n27. Treatment with radiation therapy within 7 days\n28. Treatment with a tyrosine kinase inhibitor (TKI) within 7 days or 5 half-lives (whichever is longer) before conditioning regimen\n29. Hematopoietic growth factors \\\u003C2 days\n\n    At either time:\n30. Treatment with experimental CAR T cell product unless approved by Medical Monitor\n31. Treatment with other cancer therapy including investigational agents that do not fit in the above categories within 14 days\n32. Major surgery within 14 days\n\n    Other\n33. Pregnant or lactating\n34. Any other issue which, in the opinion of the treating physician, would make the participant ineligible for the study","100 Years",{"count":78,"type":21},79,[24],"This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\\^6 cells (flat dosing).",[82,83,84,85,86,87,88],"Non-Hodgkin Lymphoma, Adult","Non-Hodgkin Lymphoma, Refractory","Non-Hodgkin Lymphoma, Relapsed","Non Hodgkin Lymphoma","Hodgkin Lymphoma","Hodgkin Lymphoma, Adult","Hodgkin's Lymphoma, Relapsed, Adult",[90,91],"NHL","Lymphoma","2025-08-14",{"date":94,"type":34},"2025-08-20",{"date":96,"type":34},"2023-01-02",{"date":98,"type":21},"2028-02-28",{"name":40,"class":41},7,""]